Meet Mason

Watch Mason's video

Mason (11 years old), a real VILTEPSO patient and compensated spokesperson. Each patient’s experience is unique.
Ask your doctor if VILTEPSO would be right for you or your loved one.*

Mason's Journey

Learn how Mason gets his weekly infusions at home with a registered nurse, and hear his mom Rebecca’s message of hope to other caregivers.

Watch Mason's story

Mason

What has your family’s journey with Duchenne been like?

Rebecca Keller, Mason’s mom

Our journey started when Mason was about one and a half years old. He had gross motor delays, which we ended up investigating and finding out he had Duchenne muscular dystrophy. That process took several months. We were in Philadelphia at the time, and then we’ve kind of moved around trying to find the best care that we can for Mason.

Mason
Mason

When did Mason start taking VILTEPSO?

Mason started VILTEPSO in the spring of 2021.

What are the VILTEPSO home infusions like?

It’s been really great having a nurse here at home, and not having to go to an infusion center and see somebody new every time. He’s had the same nurse for several months now, and we use a cream that works really well to help make him comfortable.

How does Mason inspire you?

Something I really love about Mason is that he doesn’t see himself differently from any other kid. He’s also very quick to push me aside and say, “I can do this.” And I have to trust him and his process. That’s been really good for me.

Mason
Mason

If you could say one thing to another caregiver of a child with Duchenne, what would it be?

I would say that you’re stronger than you know. You don’t realize when you hear that diagnosis how many hopes and dreams you need to let go, and how much it can change your life. But you also recalibrate and say, “How important were those things?” It really helps to put what’s most important into focus.

Explore some of our other VILTEPSO Heroes

Roland

Roland

4 years old

Hear Roland’s parents and grandparents describe how Roland was able to start VILTEPSO soon after being diagnosed,...

Diego

Diego

19 years old

Hear Diego’s mom Leslie explain why she moved with her sons to the U.S. so Diego could get access to VILTEPSO,...

Michael

Michael

14 years old

Hear Michael’s brothers describe how Michael views Duchenne as more of a special ability than a disability, and...

*These stories describe unique experiences with VILTEPSO and are not intended to represent the average individual’s response. Individual patient results with VILTEPSO may vary.

Learn about VILTEPSO’s efficacy data, and
the four-year, open-label extension study

See Efficacy & Safety Data
Close
Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.

For more information about VILTEPSO, see full Prescribing Information.